Skip to main
PRVA
PRVA logo

PRVA Stock Forecast & Price Target

PRVA Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 67%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Privia Health Group Inc has demonstrated robust growth, achieving a 20% year-over-year increase in MSSP beneficiaries and improving its savings rate by 150 basis points following its strategic acquisition of CMG in Connecticut for approximately $25 million. The company has successfully implemented over 100 providers in the market, indicating its effective execution of Care Partners type deals focused on value-based care economics. Additionally, while Privia aims to expand quickly through partnerships with larger health systems and medical groups, enhancing organic provider growth in existing markets is a critical milestone for achieving long-term targets.

Bears say

Privia Health Group Inc faces significant challenges due to anticipated declines in Medicaid enrollment, with estimates reflecting an 8%-10% decrease by year-end as a result of re-determination activities following the conclusion of the public health emergency. This reduction in Medicaid membership is likely to impact the company's revenue streams and overall profitability, as the reliance on Medicaid support is an integral part of their business model. Furthermore, sustained declines in Medicaid operations, as indicated by guidance from operating partners, may lead to an erosion of market confidence and hinder growth prospects for Privia Health.

PRVA has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 67% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Privia Health Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Privia Health Group (PRVA) Forecast

Analysts have given PRVA a Buy based on their latest research and market trends.

According to 12 analysts, PRVA has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Privia Health Group (PRVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.